Integrin α3β1 as a breast cancer target

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 10, 2011, Pages 1197-1210

  Subbaram, Sita ^a   Dipersio, C Michael ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

breast cancer; cell adhesion; cyclooxygenase 2 (Cox 2); extracellular matrix; integrin 3 1; laminin; matrix metalloproteinase 9 (MMP 9); tetraspanin CD151

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA3 INTEGRIN; ALPHA6BETA4 INTEGRIN; ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; BETA1 INTEGRIN; CD151 ANTIGEN; CELECOXIB; CELL SURFACE PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FOCAL ADHESION KINASE; GELATINASE B; LAMININ; MESSENGER RNA; ROFECOXIB; VALDECOXIB; VASCULOTROPIN;

AUTOPHOSPHORYLATION; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL ADHESION; CELL HETEROGENEITY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOPLASM; EPIDERMIS; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

BREAST NEOPLASMS; FEMALE; HUMANS; INTEGRIN ALPHA3BETA1; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 80052883301     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.609557     Document Type: Review

References (116)

1. Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res 2010;12(Suppl 2):S1
2. Weiner LM. Building better magic bullets-improving unconjugated monoclonal antibody therapy for cancer. Nat Rev Cancer 2007;7:701-6 (Pubitemid 47327414)
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42 (Pubitemid 38702844)
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92 (Pubitemid 32222155)
5. Brackstone M, Townson JL, Chambers AF. Tumour dormancy in breast cancer: an update. Breast Cancer Res 2007;9:208-14
6. Kiely BE, Soon YY, Tattersall MH, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 2011;29:456-63
7. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87 (Pubitemid 35283958)
8. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22
9. Kass L, Erler JT, Dembo M, Weaver VM. Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. Int J Biochem Cell Biol 2007;39:1987-94 (Pubitemid 47369248)
10. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science 2003;302:1704-9 (Pubitemid 37505725)
11. Delon I, Brown NH. Integrins and the actin cytoskeleton. Curr Opin Cell Biol 2007;19:43-50 (Pubitemid 46123977)
12. Brakebusch C, Bouvard D, Stanchi F, et al. Integrins in invasive growth. J Clin Invest 2002;109:999-1006 (Pubitemid 34408573)
13. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5:816-26 (Pubitemid 39336275)
14. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007;25:1637-8 (Pubitemid 46797938)
15. Schwartz MA, Ginsberg MH. Networks and crosstalk: integrin signalling spreads. Nat Cell Biol 2002;4:E65-8 (Pubitemid 34308840)
16. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004;23:7928-46 (Pubitemid 39468852)
17. Brunton VG, Frame MC. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 2008;8:427-32
18. Guan JL. Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer. IUBMB Life 2010;62:268-76
19. Choma DP, Milano V, Pumiglia KM, DiPersio CM. Integrin alpha3beta1-dependent activation of FAK/Src regulates Rac1-mediated keratinocyte polarization on laminin-5. J Invest Dermatol 2007;127:31-40 (Pubitemid 46005658)
20. Raymond K, Cagnet S, Kreft M, et al. Control of mammary myoepithelial cell contractile function by alpha3beta1 integrin signalling. EMBO J 2011;30:1896-906
21. Chapman HA, Wei Y, Simon DI, Waltz DA. Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb Haemost 1999;82:291-7
22. Porter JC, Hogg N. Integrins take partners: cross-talk between integrins and other membrane receptors. Trends Cell Biol 1998;8:390-6 (Pubitemid 28458704)
23. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005;6:801-11 (Pubitemid 41726118)
24. Del Pozo MA, Schwartz MA. Rac, membrane heterogeneity, caveolin and regulation of growth by integrins. Trends Cell Biol 2007;17:246-50 (Pubitemid 46679242)
25. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010;9:804-20
26. Stipp CS. Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets. Expert Rev Mol Med 2010;12(e3):published online 18 January 2010; doi: 10.1017/S1462399409001355
27. Mitchell K, Svenson KB, Longmate WM, et al. Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells. Cancer Res 2010;70:6359-67
28. Chung J, Mercurio AM. Contributions of the alpha6 integrins to breast carcinoma survival and progression. Mol Cells 2004;17:203-9 (Pubitemid 39137066)
29. Wang H, Fu W, Im JH, et al. Tumor cell alpha3beta1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol 2004;164:935-41 (Pubitemid 38366904)
30. Yang XH, Richardson AL, Torres-Arzayus MI, et al. CD151 accelerates breast cancer by regulating alpha6 integrin function, signaling, and molecular organization. Cancer Res 2008;68:3204-13
31. Ramirez NE, Zhang Z, Madamanchi A, et al. The alpha2beta1 integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011;121:226-37
32. Kreidberg JA. Functions of alpha3beta1 integrin. Curr Opin Cell Biol 2000;12:548-53
33. Miyazaki K. Laminin-5 (laminin-332): unique biological activity and role in tumor growth and invasion. Cancer Sci 2006;97:91-8 (Pubitemid 43379475)
34. Chia J, Kusuma N, Anderson R, et al. Evidence for a role of tumor-derived laminin-511 in the metastatic progression of breast cancer. Am J Pathol 2007;170:2135-48 (Pubitemid 47339285)
35. Marinkovich MP. Tumour microenvironment: laminin 332 in squamous-cell carcinoma. Nat Rev Cancer 2007;7:370-80 (Pubitemid 46652480)
36. DiPersio CM, Hodivala-Dilke KM, Jaenisch R, et al. alpha3beta1 Integrin is required for normal development of the epidermal basement membrane. J Cell Biol 1997;137:729-42 (Pubitemid 27200673)
37. Conti FJ, Rudling RJ, Robson A, Hodivala-Dilke KM. alpha3beta1-integrin regulates hair follicle but not interfollicular morphogenesis in adult epidermis. J Cell Sci 2003;116:2737-47 (Pubitemid 36868925)
38. Mitchell K, Szekeres C, Milano V, et al. alpha3beta1 integrin in epidermis promotes wound angiogenesis and keratinocyte-to-endothelial-cell crosstalk through the induction of MRP3. J Cell Sci 2009;122: 1778-87
39. Kreidberg JA, Donovan MJ, Goldstein SL, et al. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 1996;122:3537-47 (Pubitemid 26395995)
40. Gould VE, Koukoulis GK, Virtanen I. Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Differ Dev 1990;32:409-16
41. Koukoulis GK, Virtanen I, Korhonen M, et al. Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules. Am J Pathol 1991;139:787-99
42. Naylor MJ, Li N, Cheung J, et al. Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J Cell Biol 2005;171:717-28 (Pubitemid 41668730)
43. Taddei I, Deugnier MA, Faraldo MM, et al. beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol 2008;10:716-22 (Pubitemid 351772937)
44. Klinowska TC, Alexander CM, Georges-Labouesse E, et al. Epithelial development and differentiation in the mammary gland is not dependent on alpha3 or alpha6 integrin subunits. Dev Biol 2001;233:449-67 (Pubitemid 32467688)
45. Jonjic N, Lucin K, Krstulja M, et al. Expression of beta-1 integrins on tumor cells of invasive ductal breast carcinoma. Pathol Res Pract 1993;189:979-84 (Pubitemid 23363269)
46. Yao ES, Zhang H, Chen YY, et al. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 2007;67:659-64 (Pubitemid 46192205)
47. Morini M, Mottolese M, Ferrari N, et al. The alpha3beta1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000;87:336-42 (Pubitemid 30451643)
48. Janes SM, Watt FM. Switch from alphavbeta5 to alphavbeta6 integrin expression protects squamous cell carcinomas from anoikis. J Cell Biol 2004;166:419-31 (Pubitemid 39031244)
49. Tawil NJ, Gowri V, Djoneidi M, et al. Integrin alpha3beta1 can promote adhesion and spreading of metastatic breast carcinoma cells on the lymph node stroma. Int J Cancer 1996;66:703-10 (Pubitemid 26197934)
50. Lundstrom A, Holmbom J, Lindqvist C, Nordstrom T. The role of alpha2beta1 and alpha3beta1 integrin receptors in the initial anchoring of MDA-MB-231 human breast cancer cells to cortical bone matrix. Biochem Biophys Res Commun 1998;250:735-40 (Pubitemid 28484796)
51. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44
52. McCawley LJ, Matrisian LM. Tumor progression: defining the soil round the tumor seed. Curr Biol 2001;11:R25-7 (Pubitemid 32062705)
53. Beliveau A, Mott JD, Lo A, et al. Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes Dev 2010;24:2800-11
54. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-90
55. Lamar JM, Pumiglia KM, DiPersio CM. An immortalization-dependent switch in integrin function up-regulates MMP-9 to enhance tumor cell invasion. Cancer Res 2008;68:7371-9
56. DiPersio CM, Shao M, Di Costanzo L, et al. Mouse keratinocytes immortalized with large T antigen acquire alpha3beta1 integrin-dependent secretion of MMP-9/gelatinase B. J Cell Sci 2000;113:2909-21
57. Iyer V, Pumiglia K, DiPersio CM. alpha3beta1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: a novel mechanism of integrin-mediated MMP gene expression. J Cell Sci 2005;118:1185-95 (Pubitemid 40528689)
58. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92 (Pubitemid 34270240)
59. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 inhuman prostate cancer cell lines. Mol Biol Cell 1999;10:407-16 (Pubitemid 29156481)
60. Mukhopadhyay S, Munshi HG, Kambhampati S, et al. Calcium-induced matrix metalloproteinase 9 gene expression is differentially regulated by ERK1/2 and p38 MAPK in oral keratinocytes and oral squamous cell carcinoma. J Biol Chem 2004;279:33139-46 (Pubitemid 39062958)
61. Howe LR, Chang SH, Tolle KC, et al. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 2005;65:10113-19 (Pubitemid 41541494)
62. Stasinopoulos I, O'Brien DR, Wildes F, et al. Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res 2007;5:435-42 (Pubitemid 46903952)
63. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-9
64. Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007;9:210-18
65. Singh-Ranger G, Salhab M, Mokbel K. The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat 2008;109:189-98 (Pubitemid 351644840)
66. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009;17:55-67
67. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58
68. Holmes MD, Chen WY, Li L, et al. Aspirin intake and survival after breast cancer. J Clin Oncol 2010;28:1467-72
69. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008;372:1756-64
70. Marnett LJ. The COXIB experience: a look in the rearview mirror. Annu Rev Pharmacol Toxicol 2009;49:265-90
71. Carpenter PM, Dao AV, Arain ZS, et al. Motility induction in breast carcinoma by mammary epithelial laminin 332 (laminin 5). Mol Cancer Res 2009;7:462-75
72. Ghosh S, Johnson JJ, Sen R, et al. Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways. J Biol Chem 2006;281:13021-9 (Pubitemid 43855211)
73. Sugiura T, Berditchevski F. Function of alpha3beta1-tetraspanin protein complexes in tumor cell invasion. Evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2). J Cell Biol 1999;146:1375-89 (Pubitemid 29477702)
74. Yauch RL, Berditchevski F, Harler MB, et al. Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration. Mol Biol Cell 1998;9:2751-65 (Pubitemid 28473659)
75. Wei Y, Eble JA, Wang Z, et al. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell 2001;12:2975-86 (Pubitemid 33062955)
76. Novitskaya V, Romanska H, Dawoud M, et al. Tetraspanin CD151 regulates growth of mammary epithelial cells in three-dimensional extracellular matrix: implication for mammary ductal carcinoma in situ. Cancer Res 2010;70:4698-708
77. Sadej R, Romanska H, Baldwin G, et al. CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res 2009;7:787-98
78. Zijlstra A, Lewis J, Degryse B, et al. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 2008;13:221-34 (Pubitemid 351318371)
79. Sadej R, Romanska H, Kavanagh D, et al. Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res 2010;70:6059-70
80. Yang XH, Flores LM, Li Q, et al. Disruption of laminin-integrin-CD151- focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 2010;70:2256-63
81. Baldwin G, Novitskaya V, Sadej R, et al. Tetraspanin CD151 regulates glycosylation of alpha3beta1 integrin. J Biol Chem 2008;283:35445-54
82. Zevian S, Winterwood NE, Stipp CS. Structure-function analysis of tetraspanin CD151 teveals distinct requirements for tumor cell behaviors mediated by alpha3beta1 versus alpha6beta4 integrin. J Biol Chem 2011;286:7496-506
83. Nishiuchi R, Sanzen N, Nada S, et al. Potentiation of the ligand-binding activity of integrin alpha3beta1 via association with tetraspanin CD151. Proc Natl Acad Sci USA 2005;102:1939-44 (Pubitemid 40261991)
84. Lammerding J, Kazarov AR, Huang H, et al. Tetraspanin CD151 regulates alpha6beta1 integrin adhesionstrengthening. Proc Natl Acad Sci USA 2003;100:7616-21 (Pubitemid 36760018)
85. Chattopadhyay N, Wang Z, Ashman LK, et al. alpha3beta1 integrin-CD151, a component of the cadherin-catenin complex, regulates PTPmu expression and cell-cell adhesion. J Cell Biol 2003;163:1351-62 (Pubitemid 38032095)
86. Tang CH, Wei Y. The urokinase receptor and integrins in cancer progression. Cell Mol Life Sci 2008;65:1916-32
87. Ghosh S, Koblinski J, Johnson J, et al. Urinary-type plasminogen activator receptor/alpha3beta1 integrin signaling, altered gene expression, and oral tumor progression. Mol Cancer Res 2010;8:145-58
88. van der Pluijm G, Sijmons B, Vloedgraven H, et al. Urokinasereceptor/ integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 2001;159:971-82 (Pubitemid 32847188)
89. Carriero MV, Del Vecchio S, Capozzoli M, et al. Urokinase receptor interacts with alphavbeta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 1999;59:5307-14 (Pubitemid 29503999)
90. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9 (Pubitemid 17052899)
91. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 2004;101:591-6 (Pubitemid 38084681)
92. Akool el S, Kleinert H, Hamada FM, et al. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol 2003;23:4901-16 (Pubitemid 36793336)
93. Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci 2001;58:266-77 (Pubitemid 32217358)
94. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, et al. A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene 1994;9:1925-9 (Pubitemid 24194159)
95. Dixon DA, Tolley ND, King PH, et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001;108:1657-65 (Pubitemid 33144876)
96. Subbaram S, Kuentzel M, Frank D, et al. Determination of alternate splicing events using the Affymetrix Exon 1.0 ST arrays. Methods Mol Biol 2010;632:63-72
97. Winzen R, Kracht M, Ritter B, et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J 1999;18:4969-80 (Pubitemid 29443799)
98. Pages G, Berra E, Milanini J, et al. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 2000;275:26484-91
99. Yang X, Wang W, Fan J, et al. Prostaglandin A2-mediated stabilization of p21 mRNA through an ERK-dependent pathway requiring the RNA-binding protein HuR. J Biol Chem 2004;279:49298-306 (Pubitemid 39625816)
100. Lasa M, Mahtani KR, Finch A, et al. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol 2000;20:4265-74 (Pubitemid 30346621)
101. Montero L, Nagamine Y. Regulation by p38 mitogen-activated protein kinase of adenylate- and uridylate-rich elementmediated urokinase-type plasminogen activator (uPA) messenger RNA stability and uPA-dependent in vitro cell invasion. Cancer Res 1999;59:5286-93 (Pubitemid 29503996)
102. Han Q, Leng J, Bian D, et al. Rac1- MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells. J Biol Chem 2002;277:48379-85 (Pubitemid 35470794)
103. Bromann PA, Korkaya H, Webb CP, et al. Platelet-derived growth factor stimulates Src-dependent mRNA stabilization of specific early genes in fibroblasts. J Biol Chem 2005;280:10253-63 (Pubitemid 40395881)
104. Choma DP, Pumiglia K, DiPersio CM. Integrin alpha3beta1 directs the stabilization of a polarized lamellipodium in epithelial cells through activation of Rac1. J Cell Sci 2004;117:3947-59 (Pubitemid 39207331)
105. Fernau NS, Fugmann D, Leyendecker M, et al. Role of HuR and p38MAPK in ultraviolet B-induced posttranscriptional regulation of COX-2 expression in the human keratinocyte cell line HaCaT. J Biol Chem 2010;285:3896-904
106. Dixon DA, Kaplan CD, McIntyre TM, et al. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3¢-untranslated region. J Biol Chem 2000;275:11750-7 (Pubitemid 30237739)
107. Malyankar UM, Rittling SR, Connor A, Denhardt DT. The mitogen-regulated protein/proliferin transcript is degraded in primary mouse embryo fibroblast but not 3T3 nuclei: altered RNA processing correlates with immortalization. Proc Natl Acad Sci USA 1994;91:335-9 (Pubitemid 24018699)
108. Winterwood NE, Varzavand A, Meland MN, et al. A critical role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell functions on laminin-5. Mol Biol Cell 2006;17:2707-21 (Pubitemid 43825507)
109. Shang M, Koshikawa N, Schenk S, Quaranta V. The LG3 module of laminin-5 harbors a binding site for integrin alpha3beta1 that promotes cell adhesion, spreading, and migration. J Biol Chem 2001;276:33045-53
110. Kunneken K, Pohlentz G, Schmidt-Hederich A, et al. Recombinant human laminin-5 domains. Effects of heterotrimerization, proteolytic processing, and N-glycosylation on alpha3beta1 integrin binding. J Biol Chem 2004;279:5184-93 (Pubitemid 38220536)
111. Zhang XP, Puzon-McLaughlin W, Irie A, et al. alpha3beta1 adhesion to laminin-5 and invasin: critical and differential role of integrin residues clustered at the boundary between alpha3 N-terminal repeats 2 and 3. Biochemistry 1999;38:14424-31
112. Krukonis ES, Dersch P, Eble JA, Isberg RR. Differential effects of integrin alpha chain mutations on invasin and natural ligand interaction. J Biol Chem 1998;273:31837-43 (Pubitemid 29177119)
113. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients withrecurrent malignant glioma. J Clin Oncol 2007;25:1651-7 (Pubitemid 46797943)
114. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009;15:392-400
115. da Silva RG, Tavora B, Robinson SD, et al. Endothelial alpha3beta1 integrin represses pathological angiogenesis and sustains endothelial-VEGF. Am J Pathol 2010;177:1534-48
116. Alexis F, Rhee JW, Richie JP, et al. New frontiers in nanotechnology for cancer treatment. Urol Oncol 2008;26:74-85